then it will be subject to the regulatory framework governing drug products. Conversely, if its primary function is that of a device, it will follow the device regulatory framework.

Take time to review the definitions provided in guidance documents published by the FDA. Carefully document your findings regarding PMOA using a flow diagram to summarize the decision process:

• Determine the functions: Clearly outline the roles of each component (drug, device, or biologics).
• Perform PMOA analysis: Use existing regulatory guidance to substantiate your findings.
• Classify your product: Ascertain the center that would oversee the review based on your analysis.

This foundational knowledge with focused documentation will be instrumental in guiding discussions with stakeholders and regulatory agencies concerning your specific combination product.

Step 2: Request for Designation (RFD)

Once the PMOA is confirmed, the next practical step is to file a Request for Designation (RFD) to the FDA. An RFD is a formal inquiry submitted to the FDA to determine the appropriate classification and regulatory pathway for your combination product. This serves as a critical communication tool that can help clarify any uncertainties around classification and responsibility.

When preparing an RFD, ensure the following components are included:

• Product description: Provide a comprehensive overview inclusive of the intended use, components, and mechanisms of action.
• Proposed PMOA: Clearly delineate the primary mode of action supported by documentation.
• Rationale for lead center assignment: Justify your proposed regulatory center based on PMOA analysis.
• Historical context: If available, include relevant historical precedents for comparability.

After submission of the RFD, expect a formal response from the FDA within 60 days. Should there be any ambiguities or need for clarification, be prepared to engage in further correspondence to refine the regulatory approach.

Step 3: Regulatory Pathway and Submission Strategy

Once the lead center is designated, preparing a submission strategy becomes paramount. Based on the PMOA and designated center, the submission may involve a New Drug Application (NDA), Biologics License Application (BLA), or a PreMarket Approval (PMA) or 510(k) for devices. Understanding the criteria and results expected from each submission type will guide you in preparing your regulatory dossier.

Consider the following aspects when developing your submission strategy:

• Identify submission type: Clearly map out which of the submission types applies to your combination product, based on interactions with FDA and your findings from the RFD.
• Compile necessary documentation: Each submission route has distinct requirements. Ensure that you collect and organize all necessary clinical data, labeling requirements, and device specifications upfront to expedite the review process.
• Regulatory compliance: Develop a compliance framework that encompasses all parts of the submission according to the respective regulatory center guidelines.

As you structure your submission, consider utilizing FDA’s Submission Standards and Templates whenever applicable to align your documents with the regulatory expectations. By taking the time to organize responses in a manner reflective of the criteria established by the FDA, your process will be smoother and more likely to result in timely approvals.

Step 4: Preparing the Dossier

With the regulatory pathway clearly defined, the next critical step is to prepare your regulatory dossier. This dossier should include all necessary documentation supporting the safety, efficacy, and quality of your combination product according to the requirements set within 21 CFR Part 4.

The dossier should contain:

• Preclinical data: Summarize findings from bench testing and other safety assessments that support product development.
• Clinical trial data: Provide a comprehensive overview of all clinical trials conducted. Ensure compliance with ICH-GCP guidelines in your research and data collection.
• Manufacturing information: Detail everything from sourcing raw materials to processes involved at manufacturing sites. Ensure that the information complies with Good Manufacturing Practices (GMP).
• Labeling and packaging: Offer examples of proposed labels and packaging, ensuring that they meet FDA requirements.

A well-documented dossier is indicative of thorough planning and a professional approach to regulatory consulting. All sections should be cross-referenced with relevant sections of 21 CFR to ensure complete compliance. Keep in mind that clarity and organization are paramount, as a well-structured dossier can significantly influence review timelines and outcomes.

Step 5: Submission and Interaction with the FDA

Once the dossier is prepared, it is time to submit it to the FDA. Each submission must be done electronically via the Electronic Submissions Gateway (ESG) in line with FDA’s eSubmission standards. Follow these procedural steps:

• Validate your submission: Utilize the tools provided by FDA to check that your submission files are correct, complete, and accessible.
• Submit through ESG: Ensure that the submission complies with technical specifications outlined by FDA for electronic submissions.
• Track the submission: Once you submit, utilize the FDA’s tracking systems to monitor your submission status actively.

After submission, be prepared for possible interactions with FDA. An important aspect will be responding to any inquiries or Information Requests (IRs) during the review process. Maintain clear and timely communication, addressing any questions raised by reviewers in a thorough and organized manner.

Step 6: Post-Approval Commitments and Compliance

Following approval, you will need to execute a comprehensive plan for post-approval compliance and monitoring. This includes understanding and adhering to the post-marketing requirements mandated by the FDA. Monitor your product’s performance and maintain communication with stakeholders while managing any adverse event reports that may arise post-launch.

Key aspects of post-approval commitments include:

• Surveillance and Reporting: Develop an adverse event reporting system that complies with FDA requirements for both drugs and devices.
• Risk Management: Implement a robust risk management plan to identify, assess, and mitigate any potential risks associated with the combination product.
• Periodic Reporting: Be ready to submit periodic safety updates and other required reports as mandated by regulatory officials.

Establish a cross-functional team to oversee ongoing compliance, which includes representatives from regulatory affairs, quality assurance, clinical development, and safety monitoring. This team will have the responsibility to adapt strategies based on emerging data or regulatory changes, ensuring continued compliance with the evolving regulatory landscape.

Conclusion

Successfully navigating the complexities of FDA combination product consulting in 2023 requires a strategic understanding of PMOA, lead center designation, and submission processes. Each step in this step-by-step guide—from understanding combination products to compliance post-approval—is crucial for ensuring a successful product lifecycle. With careful planning and diligent execution, you can position your combination product for successful review and post-market success.